NO20050472L - Forbedret transdermalt leveringssystem for administrering av rotigotin - Google Patents

Forbedret transdermalt leveringssystem for administrering av rotigotin

Info

Publication number
NO20050472L
NO20050472L NO20050472A NO20050472A NO20050472L NO 20050472 L NO20050472 L NO 20050472L NO 20050472 A NO20050472 A NO 20050472A NO 20050472 A NO20050472 A NO 20050472A NO 20050472 L NO20050472 L NO 20050472L
Authority
NO
Norway
Prior art keywords
rotigotine
matrix
tds
delivery system
transdermal delivery
Prior art date
Application number
NO20050472A
Other languages
English (en)
Other versions
NO333297B1 (no
Inventor
Hans-Michael Wolff
Dietrich Wilhelm Schacht
Mike Hannay
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of NO20050472L publication Critical patent/NO20050472L/no
Publication of NO333297B1 publication Critical patent/NO333297B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Det er beskrevet et forbedret transdermalt leveringssystem (TDS) som omfatter et rygglag inert til komponentene i matriks, en selvklebende matriks som inneholder rotigotin og beskyttende foil eller ark som skal fjernes før anvendelse, kjennetegnet ved at den selvklebende matriks består av en fast eller halvfast semipermeabel polyrner (1) hvori rotigotin i sin frie baseform er blitt inkorporert, (2) som er mettet med rotigotin og inneholder nevnte rotigotin som et flertall av mikroreservoarer i matriks, (3) som er meget permeabel for den fri basen til rotigotin, (4) som er impermeabel for den protonerte. form av rotigotin, (5) hvori den maksimale diameter til mikroreservoarene er mindre enn tykkelsen på matriks. Nevnte TDS tilveiebringer en øket fluks av rotigotin over TDS/hudgrensesnittet.
NO20050472A 2002-07-30 2005-01-27 Forbedret transdermalt leveringssystem for administrering av rotigotin NO333297B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02016860A EP1386605A1 (en) 2002-07-30 2002-07-30 Improved transdermal delivery system for the administration of rotigotine
PCT/EP2003/008320 WO2004012730A1 (en) 2002-07-30 2003-07-28 Improved transdermal delivery system for the administration of rotigotine

Publications (2)

Publication Number Publication Date
NO20050472L true NO20050472L (no) 2005-01-27
NO333297B1 NO333297B1 (no) 2013-04-29

Family

ID=30011090

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050472A NO333297B1 (no) 2002-07-30 2005-01-27 Forbedret transdermalt leveringssystem for administrering av rotigotin

Country Status (19)

Country Link
EP (2) EP1386605A1 (no)
JP (2) JP4837916B2 (no)
KR (1) KR101016838B1 (no)
CN (2) CN1671375A (no)
AT (1) ATE322263T1 (no)
AU (1) AU2003258539B2 (no)
BR (1) BR0313091A (no)
CA (1) CA2491366A1 (no)
DE (1) DE60304477T2 (no)
DK (1) DK1524975T3 (no)
ES (1) ES2256780T3 (no)
IL (1) IL165918A0 (no)
MX (1) MXPA05000350A (no)
NO (1) NO333297B1 (no)
PL (1) PL217079B1 (no)
PT (1) PT1524975E (no)
SI (1) SI1524975T1 (no)
WO (1) WO2004012730A1 (no)
ZA (1) ZA200500252B (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
EP1386604A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system
DE10361259A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
WO2006039532A2 (en) * 2004-09-29 2006-04-13 Schwarz Pharma, Inc. Transdermal therapeutic system for parkinson’s disease
US7353034B2 (en) 2005-04-04 2008-04-01 X One, Inc. Location sharing and tracking using mobile phones or other wireless devices
US20100086582A1 (en) * 2008-10-06 2010-04-08 Mylan Technologies, Inc. Amorphous rotigotine transdermal system
DE102008060203A1 (de) 2008-12-07 2010-06-10 Dietrich Wilhelm Schacht Wirkstoffstabilisierende flächenförmige Vorrichtung
EP2201941A1 (de) 2008-12-29 2010-06-30 UCB Pharma GmbH Pflaster-Herstellungstechnologie
HUE039447T2 (hu) * 2009-12-22 2018-12-28 Ucb Biopharma Sprl Polivinilpirrolidon rotigotin nem kristályos formája szilárd diszperziójának stabilizálására
AP3030A (en) 2010-04-30 2014-11-30 Teikoku Pharma Usa Inc Propynylaminoindan transdermal compositions
US9119799B2 (en) 2011-03-24 2015-09-01 Teikoku Pharma Usa, Inc. Transdermal compositions comprising an active agent layer and an active agent conversion layer
EP2559435A1 (en) 2011-08-19 2013-02-20 UCB Pharma GmbH Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke
EP2776020B1 (en) 2011-11-09 2019-09-11 Teikoku Seiyaku Co., Ltd. Methods for the treatment of skin neoplasms
DE102011119043A1 (de) 2011-11-22 2013-05-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TDS) mit Rotigotin
DE102011090178A1 (de) 2011-12-30 2013-07-04 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation
CA2878376C (en) * 2012-07-05 2018-08-07 Sk Chemicals Co., Ltd. Transdermally absorbable preparation containing rotigotine
EP2914249B1 (en) 2012-11-02 2020-06-17 Teikoku Seiyaku Co., Ltd. Propynylaminoindan transdermal compositions
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
JP2016135744A (ja) * 2013-05-08 2016-07-28 株式会社 ケイ・エム トランスダーム 貼付剤
US20160199316A1 (en) 2013-06-14 2016-07-14 Tesa Labtec Gmbh Three-layer transdermal therapy system (tts)
WO2014198422A1 (de) 2013-06-14 2014-12-18 Tesa Labtec Gmbh Transdermales therapiesystem (tts) mit rotigotin
BR112015032929B1 (pt) 2013-07-03 2022-08-23 Lts Lohmann Therapie-Systeme Ag Sistema terapêutico transdérmico com componente eletrônico e métodos de produção de um sistema terapêutico transdérmico
WO2015177212A1 (en) 2014-05-20 2015-11-26 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
CN106456567A (zh) * 2014-05-20 2017-02-22 Lts勒曼治疗系统股份公司 在经皮递送系统中调节活性剂释放的方法
ES2924899T3 (es) 2014-05-20 2022-10-11 Lts Lohmann Therapie Systeme Ag Sistema de administración transdérmica que contiene rotigotina
KR102364378B1 (ko) * 2014-05-21 2022-02-16 에스케이케미칼 주식회사 안정성을 향상시킨 로티고틴 함유 경피흡수제제
CN104382850B (zh) * 2014-10-17 2017-12-22 烟台大学 一种罗替戈汀微乳及微乳凝胶
WO2019234662A1 (en) * 2018-06-07 2019-12-12 Nal Pharmaceutical Group Limited Transdermal drug delivery system containing rotigotine
DK3854388T3 (da) 2020-01-24 2023-11-27 Luye Pharma Switzerland Ag Transdermalt terapeutisk system omfattende rotigotin og mindst et ikke-aminresistent silikoneklæbestof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989586A (en) * 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
DE19814083C2 (de) * 1998-03-30 2002-02-07 Lohmann Therapie Syst Lts Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19940238A1 (de) * 1999-08-25 2001-03-01 Lohmann Therapie Syst Lts Wirkstoffhaltiges therapeutisches System zur Applikation auf der Haut mit mindestens zwei polymerhaltigen Schichten
ATE246919T1 (de) * 2001-05-08 2003-08-15 Sanol Arznei Schwarz Gmbh Verbessertes transdermales therapeutisches system zur behandlung von morbus parkinson
EP1386604A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine

Also Published As

Publication number Publication date
EP1524975A1 (en) 2005-04-27
SI1524975T1 (sl) 2006-06-30
BR0313091A (pt) 2005-06-21
MXPA05000350A (es) 2005-03-31
CA2491366A1 (en) 2004-02-12
PL374814A1 (en) 2005-10-31
IL165918A0 (en) 2006-01-15
EP1386605A1 (en) 2004-02-04
JP5564469B2 (ja) 2014-07-30
JP2005535687A (ja) 2005-11-24
ZA200500252B (en) 2006-01-25
DE60304477D1 (de) 2006-05-18
PL217079B1 (pl) 2014-06-30
DE60304477T2 (de) 2006-12-14
CN101953819A (zh) 2011-01-26
AU2003258539B2 (en) 2008-08-21
KR20050056942A (ko) 2005-06-16
KR101016838B1 (ko) 2011-02-22
EP1524975B9 (en) 2012-02-22
ES2256780T3 (es) 2006-07-16
AU2003258539A1 (en) 2004-02-23
ATE322263T1 (de) 2006-04-15
JP2011219485A (ja) 2011-11-04
WO2004012730A1 (en) 2004-02-12
JP4837916B2 (ja) 2011-12-14
NO333297B1 (no) 2013-04-29
PT1524975E (pt) 2006-07-31
DK1524975T3 (da) 2006-07-31
EP1524975B1 (en) 2006-04-05
CN1671375A (zh) 2005-09-21

Similar Documents

Publication Publication Date Title
NO20050472L (no) Forbedret transdermalt leveringssystem for administrering av rotigotin
HK1083458A1 (en) Improved transdermal delivery system
MXPA04001676A (es) Sistema terapeutico transdermico con fentanilo o sustancias relacionadas.
TW570815B (en) Transdermal therapeutic system (TTS) containing the active substance fentanyl
DK0474647T3 (da) Fremgangsmåde og indretning til frigivelse af lægemidler til huden
RU2009137122A (ru) Устройство для трансдермального введения бисопролола
DK1143938T3 (da) Transdermalt terapeutisk system med en selvklæbende matrix, der indeholder organiske syreadditionssalte af alkaloider af morphin- eller morphin-type
DK1251853T3 (da) Transdermalt terapeutisk system til indgivelse af zaleplon
ATE214606T1 (de) Transdermales therapeutisches system mit dem wirkstoff scopolaminbase
DE20221161U1 (de) Transdermales therapeutisches System mit Fentanyl bzw. verwandten Substanzen
ATE485817T1 (de) Pflaster, enthaltend fentanylum

Legal Events

Date Code Title Description
MK1K Patent expired